# Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

> **NCT04856085** · PHASE2 · COMPLETED · sponsor: **Vir Biotechnology, Inc.** · enrollment: 244 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** VIR-2218
- **DRUG:** VIR-3434
- **DRUG:** PEG-IFNα

## Key facts

- **NCT ID:** NCT04856085
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-11
- **Primary completion:** 2026-03-16
- **Final completion:** 2026-03-16
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04856085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04856085, "Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04856085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*